Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (November 2018)
23 slides from Immutep's shareholder meeting presentation, Nov 16, 2018
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics CEO Presentation Annual General Meeting November 2018 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: 2018 Summary
2018 Summary For personal use only • Strong operational and financial progress Ticker ASX: IMM; NASDAQ: IMMP • Continued focus on LAG-3 immunotherapy Ordinary Shares / ADR 71% / 29% Market Cap (12 Nov 18) A$136M • Progressed the development of four LAG-3 based product candidates for cancer and auto
Slide 4: Highlights of past months: Corporate
Highlights of past 12 months For personal use only Corporate • Name change to Immutep to reflect new focus on LAG-3 immunotherapeutics • Sound financial management • ASX Placement and SPP raising A$13.16 million • R&D cash rebates received from Australian & French schemes • Presentations at SITC, Wo
Slide 5: Highlights of past months: R&D
Highlights of past 12 months For personal use only R&D • TACTI-mel Phase I expanded to a fourth cohort due to encouraging interim data & positive safety review • Additional AIPAC Phase IIb clinical sites opened and commenced treating patients for randomised phase, recruitment of 160 patients (Nov 16
Slide 6: Highlights of past months: Collaborations
Highlights of past 12 months For personal use only Collaborations • New collaboration & supply agreement with Merck & Co (US), adding a new Phase II trial • Novartis added another three Phase II trials for LAG525 (from IMP701 antibody) • Milestone payments from Novartis and EOC Pharma • GSK complete
Slide 7: Key Financials FY18
Key Financials FY18 For personal use only Revenue and other income FY18 A$7.4M (FY17: A$4.2M) Includes milestone payments from Novartis and EOC Pharma G&A Expenses FY18 A$7.2M (FY17: A$4.3M) Increase due to financings and non cash expenses R&D and IP Expenses FY18 A$10.0M (FY17 A$7.5M) Increase due
Slide 8: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Immutep is the leader in developing LAG-3 modulating therapeutics Program Eftilagimod Alpha (IMP321) LAG525 (IMP701) GSK2831781 (IMP731) Relatlimab Company BMS Late stage 1 1 trial trial 2 trials Phase 2 1 trial 4 trials 9 trials Phase 1 3 t
Slide 9: Program Update
9 For personal use only Program Update
Slide 10: Oncology and Autoimmune Pipeline (AGM 2017)
Oncology and Autoimmune Pipeline (AGM 2017) For personal use only 10
Slide 11: Oncology and Autoimmune Pipeline
Oncology and Autoimmune Pipeline* For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights/Partners AIPAC 2019 (Chemo-IO Combo) Eftilagimod Alpha TACTI-002 (1) 2019/2020 § Global (LAG-3lg or IMP321), (IO-IO Combo) Rights APC activating (2),(3),(5) INSIGHT-004 fusion pr
Slide 12: Lead Program Eftilagimod Alpha (IMP321) Update
For personal use only Lead Program Eftilagimod Alpha (IMP321) Update 12
Slide 13: Opportunities for Eftilagimod Alpha
Opportunities for Eftilagimod Alpha For personal use only Eftilagimod has the potential to be an ideal combination candidate in oncology therapy that could improve the prognosis for patients Eftilagimod Key Characteristics (based on current data): • First in class MHCII agonist • Excellent safety pr
Slide 14: Eftilagimod Alpha in MBC (AIPAC)
Eftilagimod Alpha in MBC (AIPAC) (chemo-immunotherapy) For personal use only AIPAC trial (Phase IIb): Active Immunotherapy PAClitaxel, MBC patients, different EU countries Arm 1, 113 patients: Phase IIb, Safety-run in, paclitaxel + IMP321 Run-in: recommended multinational, 15 (6+9) patients, Stage 2
Slide 15: Efti (IMP321) in Melanoma: TACTI-mel Trial Design
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Trial Design For personal use only TACTI-mel = Two ACTive Immunotherapeutics in melanoma Recommended Phase I, multicenter, 24 patients, Efti (IMP321) + Phase II dose, open label, 4 cohorts of 6 patients anti-PD-1 (Keytruda) safety and dose esca
Slide 16: Efti (IMP321) – Clinical Development: TACTI-002 Trial Design
Efti (IMP321) – Clinical Development TACTI-002 Trial Design TACTI-002; a basket trial: Two ACTive Immunotherapeutics in different indications For personal use only Efti (IMP321) + Pembrolizumab Simon 2 stage; 3 Phase II, multi- Response rate; PFS, OS, (Keytruda) for 12 months + indications; up to 1
Slide 17: Collaboration and Supply Agreement
Collaboration and Supply Agreement For personal use only • In September 2018, Immutep entered into clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“
Slide 18: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships For personal use only • Milestone and royalty bearing partnership for Immutep • Chinese IND for IMP321 granted in Dec 2017 -> USD1m milestone paid to Immutep • EOC, an Eddingpharm spin-off holding the Chinese rights for IMP321 • Phase I program in MBC expected to start
Slide 19: IMP761 (Autoimmune Diseases)
For personal use only IMP761 (Autoimmune Diseases) 19
Slide 20: IMP761 – Agonist mAb
IMP761 – Agonist mAb For personal use only Key Characteristics IMP761 • Humanised IgG4 monoclonal antibody • First and best in class LAG-3 agonist mAb • Mechanism of action: temporarily switches off LAG-3 positive chronically activated T-Cells Development Activities In vitro/ in vivo studies compl
Slide 21: Outlook
21 For personal use only Outlook
Slide 22: Outlook
Outlook For personal use only Immutep is optimistic for the new financial year, expecting to report multiple clinical news flow items and milestones in FY19 and beyond. Clinical TACTI-mel final data: H2 2019 (updates beforehand) TACTI-002 early 2019 start in different countries TACTI-002 first data
Slide 23: Thank you!
23 For personal use only Thank you!